Synaptic Therapy in Alzheimer’s Disease: A CREB-centric Approach

Neurotherapeutics

Volumn 12, Issue 1, 2015, Pages 29-41

  Teich, Andrew F ^a   Nicholls, Russell E ^a   Puzzo, Daniela ^b   Fiorito, Jole ^a   Purgatorio, Rosa ^a   Fa’, Mauro ^a   Arancio, Ottavio ^a  

^a NewYork Presbyterian Hospital   (United States)

^b UNIVERSITY OF CATANIA   (Italy)

Author keywords

Calpains; cAMP PKA CREB cascade; ERK1 2 MAP kinase pathway; HAT; HDAC; NO cascade

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; BUNGAROTOXIN RECEPTOR; CALPAIN; CYCLIC AMP; CYCLIC AMP BINDING PROTEIN; GUANINE NUCLEOTIDE BINDING PROTEIN; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE; METABOTROPIC RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 7; N METHYL DEXTRO ASPARTIC ACID; NEUROTROPHIN RECEPTOR P75; NITRIC OXIDE; PROTEIN SERINE THREONINE KINASE; STRESS ACTIVATED PROTEIN KINASE; UBIQUITINATED PROTEIN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN;

ALZHEIMER DISEASE; AMNESIA; ASSOCIATIVE MEMORY; BRAIN FUNCTION; CALCIUM CELL LEVEL; CALCIUM HOMEOSTASIS; CELL SURVIVAL; CONTROLLED CLINICAL TRIAL (TOPIC); DISEASE COURSE; DNA BINDING; DNA TRANSCRIPTION; ENZYME ACTIVE SITE; HISTONE ACETYLATION; MEMORY CONSOLIDATION; MEMORY DISORDER; MOLECULAR INTERACTION; NERVE CELL PLASTICITY; NEUROTRANSMITTER RELEASE; NITROSYLATION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; REVIEW; SIGNAL TRANSDUCTION; UBIQUITINATION; ANIMAL; HUMAN; METABOLISM; PATHOLOGY; PHYSIOLOGY; SYNAPSE; SYNAPTIC TRANSMISSION;

ALZHEIMER DISEASE; ANIMALS; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; HUMANS; SYNAPSES; SYNAPTIC TRANSMISSION;

EID: 84926612728     PISSN: 19337213     EISSN: 18787479     Source Type: Journal    
DOI: 10.1007/s13311-014-0327-5     Document Type: Review

References (199)

1. Masliah E. Mechanisms of synaptic dysfunction in Alzheimer's disease. Histol Histopathol 1995;10:509-519.
2. Selkoe DJ. Alzheimer's disease is a synaptic failure. Science 2002;298:789-791.
3. Vitolo OV, Sant'Angelo A, Costanzo V et al. Amyloid beta-peptide inhibition of the PKA/CREB pathway and long-term potentiation: reversibility by drugs that enhance cAMP signaling. Proc Natl Acad Sci U S A 2002;99:13217-13221.
4. Kandel ER. The molecular biology of memory: cAMP, PKA, CRE, CREB-1, CREB-2, and CPEB. Mol Brain 2012;5:14.
5. Silva AJ, Kogan JH, Frankland PW, Kida S. CREB and memory. Annu Rev Neurosci 1998;21:127-148.
6. Barco A, Alarcon JM, Kandel ER. Expression of constitutively active CREB protein facilitates the late phase of long-term potentiation by enhancing synaptic capture. Cell 2002;108:689-703.
7. Benito E, Barco A. CREB's control of intrinsic and synaptic plasticity: implications for CREB-dependent memory models. Trends Neurosci 2010;33:230-240.
8. Levenson JM, O' Riordan KJ, Brown KD, Trinh MA, Molfese DL, Sweatt JD. Regulation of histone acetylation during memory formation in the hippocampus. J Biol Chem 2004;279:40545-40559.
9. Alarcón JM, Malleret G, Touzani K, et al. Chromatin acetylation, memory, and LTP are impaired in CBP+/- mice: a model for the cognitive deficit in Rubinstein–Taybi syndrome and its amelioration. Neuron 2004;42:947-959.
10. Peixoto L, Abel T. The role of histone acetylation in memory formation and cognitive impairments. Neuropsychopharmacology 2013;38:62-76.
11. Korzus E, Rosenfeld MG, Mayford M. CBP histone acetyltransferase activity is a critical component of memory consolidation. Neuron 2004;42:961-972.
12. Peleg S, Sananbenesi F, Zovoilis A, et al. Altered histone acetylation is associated with age-dependent memory impairment in mice. Science 2010;328:753-756.
13. Kandel ER. The molecular biology of memory storage: a dialog between genes and synapses. Biosci Rep 2001;21:565-611.
14. Corbin JD, Krebs EG. A cyclic AMP–stimulated protein kinase in adipose tissue. Biochem Biophys Res Commun 1969;36: 328-336.
15. Du H, Guo L, Wu X, et al. Cyclophilin D deficiency rescues Abeta-impaired PKA/CREB signaling and alleviates synaptic degeneration. Biochim Biophys Acta 2014;1842:2517-2527.
16. Chen Y, Huang X, Zhang YW et al. Alzheimer's beta-secretase (BACE1) regulates the cAMP/PKA/CREB pathway independently of beta-amyloid. J Neurosci 2012;32:11390-11395.
17. Zeitlin R, Patel S, Burgess S, Arendash GW, Echeverria V. Caffeine induces beneficial changes in PKA signaling and JNK and ERK activities in the striatum and cortex of Alzheimer's transgenic mice. Brain Res 2011;1417:127-136.
18. Li S, Jin M, Zhang D et al. Environmental novelty activates beta2-adrenergic signaling to prevent the impairment of hippocampal LTP by Abeta oligomers. Neuron 2013;77:929-941.
19. Puzzo D, Privitera L, Leznik E et al. Picomolar amyloid-beta positively modulates synaptic plasticity and memory in hippocampus. J Neurosci 2008;28:14537-14545.
20. Puzzo D, Privitera L, Fa M et al. Endogenous amyloid-beta is necessary for hippocampal synaptic plasticity and memory. Ann Neurol 2011;69:819-830.
21. Ricciarelli R, Puzzo D, Bruno O et al. A novel mechanism for cyclic adenosine monophosphate-mediated memory formation: Role of amyloid beta. Ann Neurol 2014;75:602-607.
22. Azevedo MF, Faucz FR, Bimpaki E et al. Clinical and molecular genetics of the phosphodiesterases (PDEs). Endocr Rev 2014;35:195-233.
23. Conti M, Richter W, Mehats C et al. Cyclic AMP-specific PDE4 phosphodiesterases as critical components of cyclic AMP signaling. J Biol Chem 2003;278:5493-5496.
24. Houslay MD, Adams DR. PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization. Biochem J 2003;370:1-18.
25. Ke H. Implications of PDE4 structure on inhibitor selectivity across PDE families. Int J Impot Res 2004;16(Suppl. 1):S24-S27.
26. Trinchese F, Liu S, Battaglia F et al. Progressive age-related development of Alzheimer-like pathology in APP/PS1 mice. Ann Neurol 2004;55:801-814.
27. Gong B, Vitolo OV, Trinchese F et al. Persistent improvement in synaptic and cognitive functions in an Alzheimer mouse model after rolipram treatment. J Clin Invest 2004;114:1624-1634.
28. Cheng YF, Wang C, Lin HB et al. Inhibition of phosphodiesterase-4 reverses memory deficits produced by Abeta25-35 or Abeta1-40 peptide in rats. Psychopharmacology (Berl) 2010;212:181-191.
29. Zhang C, Cheng Y, Wang H et al. RNA interference-mediated knockdown of long-form phosphodiesterase-4D (PDE4D) enzyme reverses amyloid-beta42-induced memory deficits in mice. J Alzheimers Dis 2014;38:269-280.
30. Hebenstreit GF, Fellerer K, Fichte K et al. Rolipram in major depressive disorder: results of a double-blind comparative study with imipramine. Pharmacopsychiatry 1989;22:156-160.
31. Bruno O, Fedele E, Prickaerts J et al. GEBR-7b, a novel PDE4D selective inhibitor that improves memory in rodents at non-emetic doses. Br J Pharmacol 2011;164:2054-2063.
32. Sierksma AS, van den Hove DL, Pfau F et al. Improvement of spatial memory function in APPswe/PS1dE9 mice after chronic inhibition of phosphodiesterase type 4D. Neuropharmacology 2014;77:120-130.
33. de Vrij FM, Fischer DF, van Leeuwen FW, Hol EM. Protein quality control in Alzheimer's disease by the ubiquitin proteasome system. Prog Neurobiol 2004;74:249-270.
34. Setsuie R, Wada K. The functions of UCH-L1 and its relation to neurodegenerative diseases. Neurochem Int 2007;51:105-111.
35. Chain DG, Casadio A, Schacher S et al. Mechanisms for generating the autonomous cAMP-dependent protein kinase required for long-term facilitation in Aplysia. Neuron 1999;22:147-156.
36. Choi J, Levey AI, Weintraub ST et al. Oxidative modifications and down-regulation of ubiquitin carboxyl-terminal hydrolase L1 associated with idiopathic Parkinson's and Alzheimer's diseases. J Biol Chem 2004;279:13256-13264.
37. Gong B, Cao Z, Zheng P et al. Ubiquitin hydrolase uch-L1 rescues beta-amyloid-induced decreases in synaptic function and contextual memory. Cell 2006;126:775-788.
38. Smith DL, Pozueta J, Gong B, Arancio O, Shelanski M. Reversal of long-term dendritic spine alterations in Alzheimer disease models. Proc Natl Acad Sci U S A 2009;106:16877-16882.
39. Gong B, Leznik E. The role of ubiquitin C-terminal hydrolase L1 in neurodegenerative disorders. Drug News Perspect 2007;20:365-370.
40. Liu Z, Meray RK, Grammatopoulos TN et al. Membrane-associated farnesylated UCH-L1 promotes alpha-synuclein neurotoxicity and is a therapeutic target for Parkinson's disease. Proc Natl Acad Sci U S A 2009;106:4635-4640.
41. Sakamoto K, Karelina K, Obrietan K. CREB: a multifaceted regulator of neuronal plasticity and protection. J Neurochem 2011;116:1-9.
42. Coffey ET. Nuclear and cytosolic JNK signalling in neurons. Nat Rev Neurosci 2014;15:285-299.
43. Yin F, Jiang T, Cadenas E. Metabolic triad in brain aging: mitochondria, insulin/IGF-1 signalling and JNK signalling. Biochem Soc Trans 2013;41:101-105.
44. Munoz L, Ammit AJ. Targeting p38 MAPK pathway for the treatment of Alzheimer's disease. Neuropharmacology 2010;58:561-568.
45. Obara Y, Nakahata N. The signaling pathway leading to extracellular signal-regulated kinase 5 (ERK5) activation via G-proteins and ERK5-dependent neurotrophic effects. Mol Pharmacol 2010;77:10-16.
46. Keshet Y, Seger R. The MAP kinase signaling cascades: a system of hundreds of components regulates a diverse array of physiological functions. Methods Mol Biol 2010;661:3-38.
47. Arthur JS, Fong AL, Dwyer JM et al., Mitogen- and stress-activated protein kinase 1 mediates cAMP response element-binding protein phosphorylation and activation by neurotrophins. J Neurosci 2004;24:4324-4332.
48. Diniz BS, Teixeira AL. Brain-derived neurotrophic factor and Alzheimer's disease: physiopathology and beyond. Neuromolecular Med 2011;13:217-222.
49. Schulte-Herbruggen O, Jockers-Scherubl MC, Hellweg R. Neurotrophins: from pathophysiology to treatment in Alzheimer's disease. Curr Alzheimer Res 2008;5:38-44.
50. Laske C, Stransky E, Leyhe T, et al. Stage-dependent BDNF serum concentrations in Alzheimer's disease. J Neural Transm 2006;113:1217-1224.
51. Lee JG, Shin BS, You YS, et al. Decreased serum brain-derived neurotrophic factor levels in elderly korean with dementia. Psychiatry Investig 2009;6:299-305.
52. Zhang J, Sokal I, Peskind ER, et al. CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases. Am J Clin Pathol 2008;129:526-529.
53. Li G, Peskind ER, Millard SP et al. Cerebrospinal fluid concentration of brain-derived neurotrophic factor and cognitive function in non-demented subjects. PLoS One 2009;4:e5424.
54. Tong L, Balazs R, Thornton PL, Cotman CW. Beta-amyloid peptide at sublethal concentrations downregulates brain-derived neurotrophic factor functions in cultured cortical neurons. J Neurosci 2004;24:6799-6809.
55. Zhu X, Castellani RJ, Takeda A et al. Differential activation of neuronal ERK, JNK/SAPK and p38 in Alzheimer disease: the 'two hit' hypothesis. Mech Ageing Dev 2001;123:39-46.
56. Perry G, Roder H, Nunomura A et al. Activation of neuronal extracellular receptor kinase (ERK) in Alzheimer disease links oxidative stress to abnormal phosphorylation. Neuroreport 1999;10:2411-2415.
57. Ferrer I, Blanco R, Carmona M et al. Phosphorylated map kinase (ERK1, ERK2) expression is associated with early tau deposition in neurones and glial cells, but not with increased nuclear DNA vulnerability and cell death, in Alzheimer disease, Pick's disease, progressive supranuclear palsy and corticobasal degeneration. Brain Pathol 2001;11:144-158.
58. Dineley KT, Westerman M, Bui D, Bell K, Ashe KH, Sweatt JD. Beta-amyloid activates the mitogen-activated protein kinase cascade via hippocampal alpha7 nicotinic acetylcholine receptors: In vitro and in vivo mechanisms related to Alzheimer's disease. J Neurosci 2001;21:4125-4133.
59. Sweatt JD. The neuronal MAP kinase cascade: a biochemical signal integration system subserving synaptic plasticity and memory. J Neurochem 2001;76:1-10.
60. Samuels IS, Saitta SC, Landreth GE. MAP'ing CNS development and cognition: an ERKsome process. Neuron 2009;61:160-167.
61. Wang JQ, Fibuch EE, Mao L. Regulation of mitogen-activated protein kinases by glutamate receptors. J Neurochem 2007;100:1-11.
62. Werry TD, Christopoulos A Sexton PA. Mechanisms of ERK1/2 regulation by seven-transmembrane-domain receptors. Curr Pharm Design 2006;12:1683-1702.
63. De Felice FG, Velasco PT, Lambert MP et al. Abeta oligomers induce neuronal oxidative stress through an N-methyl-D-aspartate receptor-dependent mechanism that is blocked by the Alzheimer drug memantine. J Biol Chem 2007;282:11590-11601.
64. Cowburn RF, Wiehager B, Trief E, Li-Li M, Sundstrom E. Effects of beta-amyloid-(25-35) peptides on radioligand binding to excitatory amino acid receptors and voltage-dependent calcium channels: evidence for a selective affinity for the glutamate and glycine recognition sites of the NMDA receptor. Neurochem Res 1997;22:1437-1442.
65. Um JW, Kaufman AC, Kostylev M et al. Metabotropic glutamate receptor 5 is a coreceptor for Alzheimer abeta oligomer bound to cellular prion protein. Neuron 2013;79:887-902.
66. Origlia N, Arancio O, Domenici L, Yan SS. MAPK, beta-amyloid and synaptic dysfunction: the role of RAGE. Expert Rev Neurother 2009;9:1635-1645.
67. Origlia N, Criscuolo C, Arancio O, Yan SS, Domenici L. RAGE inhibition in microglia prevents ischemia-dependent synaptic dysfunction in an amyloid-enriched environment. J Neurosci 2014;34:8749-8760.
68. Balleza-Tapia H, Pena F. Pharmacology of the intracellular pathways activated by amyloid beta protein. Mini Rev Med Chem 2009;9:724-740.
69. Schettini G, Govoni S, Racchi M, Rodriguez G. Phosphorylation of APP-CTF-AICD domains and interaction with adaptor proteins: signal transduction and/or transcriptional role–relevance for Alzheimer pathology. J Neurochem 2010;115:1299-1308.
70. Knowles JK, Simmons DA, Nguyen TV et al. Small molecule p75NTR ligand prevents cognitive deficits and neurite degeneration in an Alzheimer's mouse model. Neurobiol Aging 2013;34:2052-2063.
71. Rosen LB, Simmons DA, Nguyen TV et al. Membrane depolarization and calcium influx stimulate MEK and MAP kinase via activation of Ras. Neuron 1994;12:1207-1221.
72. Sindreu CB, Scheiner ZS, Storm DR. Ca2+ -stimulated adenylyl cyclases regulate ERK-dependent activation of MSK1 during fear conditioning. Neuron 2007;53:79-89.
73. Chu CT, Levinthal DJ, Kulich SM, Chalovich EM, DeFranco DB. Oxidative neuronal injury: The dark side of ERK1/2. Eur J Biochem 2004;271:2060-2066.
74. Lee B, Cao R, Choi YS et al. The CREB/CRE transcriptional pathway: protection against oxidative stress-mediated neuronal cell death. J Neurochem 2009;108:1251-1265.
75. Drewes G, Lichtenberg-Kraag B, Doring F et al. Mitogen activated protein (MAP) kinase transforms tau protein into an Alzheimer-like state. EMBO J 1992;11:2131-2138.
76. Reynolds CH, Betts JC, Blackstock WP, Nebreda AR, Anderton BH. Phosphorylation sites on tau identified by nanoelectrospray mass spectrometry: differences in vitro between the mitogen-activated protein kinases ERK2, c-Jun N-terminal kinase and P38, and glycogen synthase kinase-3beta. J Neurochem 2000;74:1587-1595.
77. Lu Q, Wood JG. Functional studies of Alzheimer's disease tau protein. J Neurosci 1993;13:508-515.
78. Ekinci FJ, Shea TB. Hyperactivation of mitogen-activated protein kinase increases phospho-tau immunoreactivity within human neuroblastoma: additive and synergistic influence of alteration of additional kinase activities. Cell Mol Neurobiol 1999;19:249-260.
79. Guise S, Braguer D, Carles G, Delacourte A, Briand C. Hyperphosphorylation of tau is mediated by ERK activation during anticancer drug-induced apoptosis in neuroblastoma cells. J Neurosci Res 2001;63:257-267.
80. Garver TD, Oyler GA, Harris KA et al. Tau phosphorylation in brain slices: pharmacological evidence for convergent effects of protein phosphatases on tau and mitogen-activated protein kinase. Mol Pharmacol 1995;47:745-756.
81. Holzer M, Rodel L, Seeger G et al. Activation of mitogen-activated protein kinase cascade and phosphorylation of cytoskeletal proteins after neurone-specific activation of p21ras. II. Cytoskeletal proteins and dendritic morphology. Neuroscience 2001;105:1041-1054.
82. Spillantini MG, Goedert M. Tau pathology and neurodegeneration. Lancet Neurol 2013;12:609-622.
83. Rapoport M, Ferreira A. PD98059 prevents neurite degeneration induced by fibrillar beta-amyloid in mature hippocampal neurons. J Neurochem 2000;74:125-133.
84. Greenberg SM, Koo EH, Selkoe DJ, Qiu WQ, Kosik KS. Secreted beta-amyloid precursor protein stimulates mitogen-activated protein kinase and enhances tau phosphorylation. Proc Natl Acad Sci U S A 1994;91:7104-7108.
85. Desdouits-Magnen J, Desdouits F, Takeda S et al. Regulation of secretion of Alzheimer amyloid precursor protein by the mitogen-activated protein kinase cascade. J Neurochem 1998;70:524-530.
86. Mills J, Laurent Charest D, Lam F et al. Regulation of amyloid precursor protein catabolism involves the mitogen-activated protein kinase signal transduction pathway. J Neurosci 1997;17:9415-9422.
87. Kim SK, Park HJ, Hong HS, Baik EJ, Jung MW, Mook-Jung I. ERK1/2 is an endogenous negative regulator of the gamma-secretase activity. FASEB J 2006;20:157-159.
88. Tung YT, Hsu WM, Wang BJ et al. Sodium selenite inhibits gamma-secretase activity through activation of ERK. Neurosci Lett 2008;440:38-43.
89. Wan X-Z, Li B, Li Y-C et al. Activation of NMDA receptors upregulates a disintegrin and metalloproteinase 10 via a Wnt/MAPK signaling pathway. J Neurosci 2012;32:3910-3916.
90. Kojro E, Postina R, Buro C, Meiringer C, Gehrig-Burger K, Fahrenholz F. The neuropeptide PACAP promotes the alpha-secretase pathway for processing the Alzheimer amyloid precursor protein. FASEB J 2006;20:512-514.
91. Mitsuda N, Ohkubo N, Tamatani M et al. Activated cAMP-response element-binding protein regulates neuronal expression of presenilin-1. J Biol Chem 2001;276:9688-9698.
92. Hardingham N, Dachtler J, Fox K. The role of nitric oxide in pre-synaptic plasticity and homeostasis. Front Cell Neurosci 2013;7:190.
93. Puzzo D, Palmeri A, Arancio O. Involvement of the nitric oxide pathway in synaptic dysfunction following amyloid elevation in Alzheimer's disease. Rev Neurosci 2006;17:497-523.
94. Lu YF, Kandel ER, Hawkins RD. Nitric oxide signaling contributes to late-phase LTP and CREB phosphorylation in the hippocampus. J Neurosci 1999;19:10250-10261.
95. Wong JC, Bathina M, Fiscus RR. Cyclic GMP/protein kinase G type-Ialpha (PKG-Ialpha) signaling pathway promotes CREB phosphorylation and maintains higher c-IAP1, livin, survivin, and Mcl-1 expression and the inhibition of PKG-Ialpha kinase activity synergizes with cisplatin in non-small cell lung cancer cells. J Cell Biochem 2012;113:3587-3598.
96. Riccio A, Alvania RS, Lonze BE, et al. A nitric oxide signaling pathway controls CREB-mediated gene expression in neurons. Mol Cell 2006;21:283-294.
97. Bernabeu R, Schmitz P, Faillace MP, Izquierdo I, Medina JH. Hippocampal cGMP and cAMP are differentially involved in memory processing of inhibitory avoidance learning. Neuroreport 1996;7:585-588.
98. Matsumoto Y, Unoki S, Aonuma H, Mizunami M. Critical role of nitric oxide-cGMP cascade in the formation of cAMP-dependent long-term memory. Learn Mem 2006;13:35-44.
99. Rutten K, Prickaerts J, Hendrix M, van der Staay FJ, Sik A, Blokland A. Time-dependent involvement of cAMP and cGMP in consolidation of object memory: studies using selective phosphodiesterase type 2, 4 and 5 inhibitors. Eur J Pharmacol 2007;558:107-112.
100. Bollen E, Puzzo D, Rutten K, et al. Improved long-term memory via enhancing cGMP-PKG signaling requires cAMP-PKA signaling. Neuropsychopharmacology 2014;39:2497-2505.
101. Hu SC, Chrivia J, Ghosh A. Regulation of CBP-mediated transcription by neuronal calcium signaling. Neuron 1999;22:799-808.
102. Montminy M. Transcriptional regulation by cyclic AMP. Annu Rev Biochem 1997;66:807-822.
103. Tao X, Finkbeiner S, Arnold DB, Shaywitz AJ, Greenberg ME. Ca2+ influx regulates BDNF transcription by a CREB family transcription factor-dependent mechanism. Neuron 1998;20:709-726.
104. Murphy DD, Segal M. Morphological plasticity of dendritic spines in central neurons is mediated by activation of cAMP response element binding protein. Proc Natl Acad Sci U S A 1997;94:1482-1487.
105. Paris D, Town T, Parker TA, et al. Inhibition of Alzheimer's beta-amyloid induced vasoactivity and proinflammatory response in microglia by a cGMP-dependent mechanism. Exp Neurol 1999;157:211-221.
106. McCarty MF. Vascular nitric oxide may lessen Alzheimer's risk. Med Hypotheses 1998;51:465-476.
107. Suhara T, Magrane J, Rosen K, et al. Abeta42 generation is toxic to endothelial cells and inhibits eNOS function through an Akt/GSK-3beta signaling-dependent mechanism. Neurobiol Aging 2003;24:437-451.
108. Venturini G, Colasanti M, Persichini T, et al. Beta-amyloid inhibits NOS activity by subtracting NADPH availability. FASEB J 2002;16:1970-1972.
109. Baltrons MA, Pedraza CE, Heneka MT, Garcia A. Beta-amyloid peptides decrease soluble guanylyl cyclase expression in astroglial cells. Neurobiol Dis 2002;10:139-149.
110. Puzzo D, Vitolo O, Trinchese F, Jacob JP, Palmeri A, Arancio O. Amyloid-beta peptide inhibits activation of the nitric oxide/cGMP/cAMP-responsive element-binding protein pathway during hippocampal synaptic plasticity. J Neurosci 2005;25:6887-6897.
111. Miller TW, Isenberg JS, Shih HB, Wang Y, Robert DD. Amyloid-beta inhibits No-cGMP signaling in a CD36- and CD47-dependent manner. PLoS One 2010;5:e15686.
112. Puzzo D, Staniszewski A, Deng SX, et al. Phosphodiesterase 5 inhibition improves synaptic function, memory, and amyloid-beta load in an Alzheimer's disease mouse model. J Neurosci 2009;29:8075-8086.
113. Palmeri A, Privitera L, Giunta S, Loreto C, Puzzo D. Inhibition of phosphodiesterase-5 rescues age-related impairment of synaptic plasticity and memory. Behav Brain Res 2013;240:11-20.
114. Wirtz-Brugger F, Giovanni A. Guanosine 3',5'-cyclic monophosphate mediated inhibition of cell death induced by nerve growth factor withdrawal and beta-amyloid: protective effects of propentofylline. Neuroscience 2000;99:737-750.
115. Bonkale WL, Winblad B, Ravid R, Cowburn RF. Reduced nitric oxide responsive soluble guanylyl cyclase activity in the superior temporal cortex of patients with Alzheimer's disease. Neurosci Lett 1995;187:5-8.
116. Ciani E, Guidi S, Bartesaghi R, Contestabile A. Nitric oxide regulates cGMP-dependent cAMP-responsive element binding protein phosphorylation and Bcl-2 expression in cerebellar neurons: implication for a survival role of nitric oxide. J Neurochem 2002;82:1282-1289.
117. Gudi T, Casteel DE, Vinson C, Boss GR, Pilz RB. NO activation of fos promoter elements requires nuclear translocation of G-kinase I and CREB phosphorylation but is independent of MAP kinase activation. Oncogene 2000;19:6324-6333.
118. Tong L, Thornton PL, Balazs R, Cotman CW. Beta -amyloid-(1-42) impairs activity-dependent cAMP-response element-binding protein signaling in neurons at concentrations in which cell survival Is not compromised. J Biol Chem 2001;276:17301-17306.
119. Samengo G, Avik A, Fedor B, et al. Age-related loss of nitric oxide synthase in skeletal muscle causes reductions in calpain S-nitrosylation that increase myofibril degradation and sarcopenia. Aging Cell 2012;11:1036-1045.
120. Domek-Lopacinska KU, Strosznajder JB. Cyclic GMP and nitric oxide synthase in aging and Alzheimer's disease. Mol Neurobiol 2010;41:129-137.
121. Law A, O'Donnell J, Gauthier S, Quirion R. Neuronal and inducible nitric oxide synthase expressions and activities in the hippocampi and cortices of young adult, aged cognitively unimpaired, and impaired Long-Evans rats. Neuroscience 2002;112:267-275.
122. Schrage WG, Eisenach JH, Joyner MJ. Ageing reduces nitric-oxide- and prostaglandin-mediated vasodilatation in exercising humans. J Physiol 2007;579:227-236.
123. Burgaud JL, Riffaud JP, Del Soldato P. Nitric-oxide releasing molecules: a new class of drugs with several major indications. Curr Pharm Des 2002;8:201-213.
124. Jantzen PT, Connor KE, DiCarlo G, et al. Microglial activation and beta -amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice. J Neurosci 2002;22:2246-2254.
125. Thatcher GR, Bennett BM, Dringenberg HC, Reynolds JN. Novel nitrates as NO mimetics directed at Alzheimer's disease. J Alzheimers Dis 2004;6(6 Suppl.):S75-S84.
126. Thatcher GR, Bennett BM, Reynolds JN. Nitric oxide mimetic molecules as therapeutic agents in Alzheimer's disease. Curr Alzheimer Res 2005;2:171-182.
127. Wenk GL, McGann-Gramling K, Hauss-Wegrzyniak B, et al. Attenuation of chronic neuroinflammation by a nitric oxide-releasing derivative of the antioxidant ferulic acid. J Neurochem. 2004;89:484-493.
128. Fiorito J, Saeed F, Zhang H, et al. Synthesis of quinoline derivatives: discovery of a potent and selective phosphodiesterase 5 inhibitor for the treatment of Alzheimer's disease. Eur J Med Chem 2013; 60:285-294.
129. Puzzo D, Loreto C, Giunta S, et al. Effect of phosphodiesterase-5 inhibition on apoptosis and beta amyloid load in aged mice. Neurobiol Aging 2014;35:520-531.
130. Goll DE, Thompson VF, Li H, Wei W, Cong J. The calpain system. Physiol Rev 2003;83:731-801.
131. Sorimachi H, Hata S, Ono Y. Impact of genetic insights into calpain biology. J Biochem 2011;150:23-37.
132. Wu HY, Lynch DR. Calpain and synaptic function. Mol Neurobiol 2006;33:215-236.
133. Baudry M, Chou MM, Bi X. Targeting calpain in synaptic plasticity. Expert Opin Ther Targets 2013;17:579-592.
134. Cong J, Goll DE, Peterson AM, Kapprell HP. The role of autolysis in activity of the Ca2+-dependent proteinases (mu-calpain and m-calpain). J Biol Chem 1989;264:10096-10103.
135. Liu F, Grundke-Iqbal I, Iqbal K, Oda Y, Tomizawa K, Gong CX. Truncation and activation of calcineurin A by calpain I in Alzheimer disease brain. J Biol Chem 2005;280:37755-37762.
136. Saito K, Elce JS, Hamos JE, Nixon RA. Widespread activation of calcium-activated neutral proteinase (calpain) in the brain in Alzheimer disease: a potential molecular basis for neuronal degeneration. Proc Natl Acad Sci U S A 1993;90:2628-2632.
137. Hu GY, Hvalby O, Walaas SI, et al. Protein kinase C injection into hippocampal pyramidal cells elicits features of long term potentiation. Nature 1987;328:426-429.
138. Lledo, PM, Hjelmstad GO, Mukherji S, Soderling TR, Malenka RC, Nicoll RA. Calcium/calmodulin-dependent kinase II and long-term potentiation enhance synaptic transmission by the same mechanism. Proc Natl Acad Sci U S A 1995;92:11175-11179.
139. Malinow R, Schulman H, Tsien RW. Inhibition of postsynaptic PKC or CaMKII blocks induction but not expression of LTP. Science 1989;245:862-826.
140. Otmakhov N, Griffith LC, Lisman JE. Postsynaptic inhibitors of calcium/calmodulin-dependent protein kinase type II block induction but not maintenance of pairing-induced long-term potentiation. J Neurosci 1997;17:5357-5365.
141. Hajimohammadreza I, Raser KJ, Nath R, Nadimpalli R, Scott M, Wang KK. Neuronal nitric oxide synthase and calmodulin-dependent protein kinase IIalpha undergo neurotoxin-induced proteolysis. J Neurochem 1997;69:1006-1013.
142. Hrabetova S, Sacktor TC. Bidirectional regulation of protein kinase M zeta in the maintenance of long-term potentiation and long-term depression. J Neurosci 1996;16:5324-5233.
143. Wu HY, Tomizawa K, Oda Y, et al. Critical role of calpain-mediated cleavage of calcineurin in excitotoxic neurodegeneration. J Biol Chem 2004;279:4929-4940.
144. Watt F, Molloy PL. Specific cleavage of transcription factors by the thiol protease, m-calpain. Nucleic Acids Res 1993;21:5092-100.
145. Jin N, Qian W, Yin X, et al. CREB regulates the expression of neuronal glucose transporter 3: a possible mechanism related to impaired brain glucose uptake in Alzheimer's disease. Nucleic Acids Res 2013;41:3240-3256.
146. Wu X, Spiro C, Owen WG, McMurray CT. cAMP response element-binding protein monomers cooperatively assemble to form dimers on DNA. J Biol Chem 1998;273:20820-20827.
147. Ferreira A, Bigio EH. Calpain-mediated tau cleavage: a mechanism leading to neurodegeneration shared by multiple tauopathies. Mol Med 2011;17:676-685.
148. Higuchi M, Tomioka M, Takano J, et al. Distinct mechanistic roles of calpain and caspase activation in neurodegeneration as revealed in mice overexpressing their specific inhibitors. J Biol Chem 2005;280:15229-15237.
149. Patrick GN, Zukerberg L, Nikolic M, de la Monte S, Dikkes P, Tsai LH. Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature 1999;402:615-622.
150. Peterson C, Goldman JE. Alterations in calcium content and biochemical processes in cultured skin fibroblasts from aged and Alzheimer donors. Proc Natl Acad Sci U S A 1986;83:2758-2762.
151. Saitoh T, Masliah E, Jin LW, Cole GM, Wieloch T, Shapiro IP. Protein kinases and phosphorylation in neurologic disorders and cell death. Lab Invest 1991;64:596-616.
152. Tsuji T, Shimohama S, Kimura J, Shimizu K. m-Calpain (calcium-activated neutral proteinase) in Alzheimer's disease brains. Neurosci Lett 1998;248:109-112.
153. Vosler PS, Brennan CS, Chen J. Calpain-mediated signaling mechanisms in neuronal injury and neurodegeneration. Mol Neurobiol 2008;38:78-100.
154. Trinchese F, Fa M, Liu S, et al. Inhibition of calpains improves memory and synaptic transmission in a mouse model of Alzheimer disease. J Clin Invest 2008;118:2796-2807.
155. Di Rosa G, Odrijin T, Nixon RA, Arancio O. Calpain inhibitors: a treatment for Alzheimer's disease. J Mol Neurosci 2002;19:135-141.
156. Toth E, Bruin JP, Heinsbroek RP, Joosten RN. Spatial learning and memory in calpastatin-deficient rats. Neurobiol Learn Mem 1996;66:230-235.
157. Liang Z, Liu F, Grundke-Iqbal I, Iqbal K, Gong CX. Down-regulation of cAMP-dependent protein kinase by over-activated calpain in Alzheimer disease brain. J Neurochem 2007;103:2462-2470.
158. Masliah E, Mallory M, Hansen L, DeTeresa R, Alford M, Terry R. Synaptic and neuritic alterations during the progression of Alzheimer's disease. Neurosci Lett 1994;174:67-72.
159. Sheng M, Sabatini BL, Sudhof TC. Synapses and Alzheimer's disease. Cold Spring Harb Perspect Biol 2012;4(5): a005777.
160. Ferreira A. Calpain Dysregulation in Alzheimer's Disease. ISRN Biochemistry 2012;12. doi:10.5402/2012/728571
161. Liang B, Duan BY, Zhou XP, Gong JX, Luo ZG. Calpain activation promotes BACE1 expression, amyloid precursor protein processing, and amyloid plaque formation in a transgenic mouse model of Alzheimer disease. J Biol Chem 2010;285:27737-27744.
162. Grynspan F, Griffin WR, Cataldo A, Katayama S, Nixon RA. Active site-directed antibodies identify calpain II as an early-appearing and pervasive component of neurofibrillary pathology in Alzheimer's disease. Brain Res 1997;763:145-158.
163. Seo J, Giusti-Rodriguez P, Zhou Y, et al. Activity-dependent p25 generation regulates synaptic plasticity and Abeta-induced cognitive impairment. Cell 2014;157:486-498.
164. Higuchi M, Iwata N, Matsuba Y, et al. Mechanistic involvement of the calpain-calpastatin system in Alzheimer neuropathology. FASEB J 2012;26:1204-1217.
165. Donkor IO. Calpain inhibitors: a survey of compounds reported in the patent and scientific literature. Expert Opin Ther Pat 2011;21:601-636.
166. Pietsch M, Chua KC, Abell AD. Calpains: attractive targets for the development of synthetic inhibitors. Curr Top Med Chem 2010;10:270-293.
167. Hanada K, Tamai M, Yamagishi M, Ohmura S, Sawada J, Tanaka I. Isolation and Characterization of E-64, a New Thiol Protease Inhibitor. Agricultural and Biological Chemistry 1978;42:523-528.
168. Parkes C, Kembhavi AA, Barrett AJ. Calpain Inhibition by Peptide Epoxides. Biochemical Journal 1985;230:509-516.
169. Sugita H, Ishiura S, Suzuki K, Imahori K. Inhibition of Epoxide Derivatives on Chicken Calcium-Activated Neutral Protease (Canp) Invitro and Invivo. Journal of Biochemistry 1980;87:339-341.
170. Battaglia F, Trinchese F, Liu SM, Walter S, Nixon RA, Arancio O. Calpain inhibitors, a treatment for Alzheimer's disease - Position paper. Journal of Molecular Neuroscience 2003;20:357-362.
171. Schiefer IT, Tapadar S, Litosh V, et al. Design, Synthesis, and Optimization of Novel Epoxide Incorporating Peptidomimetics as Selective Calpain Inhibitors. Journal of Medicinal Chemistry 2013;56:6054-6068.
172. Citron M, Diehl TS, Gordon G, Biere AL, Seubert P, Selkoe DJ. Evidence that the 42- and 40-amino acid forms of amyloid beta protein are generated from the beta-amyloid precursor protein by different protease activities. Proc Natl Acad Sci U S A 1996;93:13170-13175.
173. Higaki J, Quon D, Zhong Z, Cordell B. Inhibition of beta-amyloid formation identifies proteolytic precursors and subcellular site of catabolism. Neuron 1995;14:651-659.
174. Nikkel AL, Martino B, Markosyan S, et al. The novel calpain inhibitor A-705253 prevents stress-induced tau hyperphosphorylation in vitro and in vivo. Neuropharmacology 2012;63:606-612.
175. Sinjoanu RC, Kleinschmidt S, Bitner RS, Brioni JD, Moeller A, Ferreira A. The novel calpain inhibitor A-705253 potently inhibits oligomeric beta-amyloid-induced dynamin 1 and tau cleavage in hippocampal neurons. Neurochemistry International 2008;53:79-88.
176. Medeiros R, Kitazawa M, Chabrier MA, et al. Calpain Inhibitor A-705253 Mitigates Alzheimer's Disease-Like Pathology and Cognitive Decline in Aged 3xTgAD Mice. American Journal of Pathology 2012;181:616-625.
177. Schneider A, Chatterjee S, Bousiges O, et al. Acetyltransferases (HATs) as targets for neurological therapeutics. Neurotherapeutics 2013;10:568-588.
178. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006;5:769-784.
179. Fischer A, Sananbenesi F, Wang X, Dobbin M, Tsai LH, et al. Recovery of learning and memory is associated with chromatin remodelling. Nature 2007;447:178-182.
180. Fontán-Lozano A, Romero-Granados R, Troncoso J, Múnera A, Delgado-García JM, Carrión AM. Histone deacetylase inhibitors improve learning consolidation in young and in KA-induced-neurodegeneration and SAMP-8-mutant mice. Mol Cell Neurosci 2008;39:193-201.
181. Hawk JD, Abel T. The role of NR4A transcription factors in memory formation. Brain Res Bull 2011;85:21-29.
182. Perez-Cadahia B, Drobic B, Davie JR. Activation and function of immediate-early genes in the nervous system. Biochem Cell Biol 2011;89:61-73.
183. Dragunow M. A role for immediate-early transcription factors in learning and memory. Behav Genet 1996;26:293-299.
184. Vecsey CG, Hawk JD, Lattal KM, et al. Histone deacetylase inhibitors enhance memory and synaptic plasticity via CREB:CBP-dependent transcriptional activation. J Neurosci 2007;27:6128-6140.
185. Stilling RM, Fischer A. The role of histone acetylation in age-associated memory impairment and Alzheimer's disease. Neurobiol Learn Mem 2011;96:19-26.
186. Francis YI, Fà M, Ashraf H, et al. Dysregulation of histone acetylation in the APP/PS1 mouse model of Alzheimer's disease. J Alzheimers Dis 2009;18:131-139.
187. Stefanko DP, Barrett RM, Ly AR, Reolon GK, Wood MA. Modulation of long-term memory for object recognition via HDAC inhibition. Proc Natl Acad Sci U S A 2009;106:9447-9452.
188. Ricobaraza A, Cuadrado-Tejedor M, Pérez-Mediavilla A, Frechilla D, Del Río J, García-Osta A. Phenylbutyrate ameliorates cognitive deficit and reduces tau pathology in an Alzheimer's disease mouse model. Neuropsychopharmacology 2009;34:1721-1732.
189. Oliveira AM, Wood MA, McDonough CB, Abel T. Transgenic mice expressing an inhibitory truncated form of p300 exhibit long-term memory deficits. Learn Mem 2007;14:564-572.
190. Maurice T, Duclot F, Meunier J, et al. Altered memory capacities and response to stress in p300/CBP-associated factor (PCAF) histone acetylase knockout mice. Neuropsychopharmacology 2008;33:1584-1602.
191. Wei W, Coelho CM, Li X, et al. p300/CBP-associated factor selectively regulates the extinction of conditioned fear. J Neurosci 2012;32:11930-11941.
192. Chatterjee S1, Mizar P, Cassel R, et al. A novel activator of CBP/p300 acetyltransferases promotes neurogenesis and extends memory duration in adult mice. J Neurosci 2013;33:10698-10712.
193. Wu J, Anwyl R, Rowan MJ. beta-Amyloid-(1-40) increases long-term potentiation in rat hippocampus in vitro. Eur J Pharmacol 1995;284:R1-R3.
194. Kowalska MA, Badellino K. beta-Amyloid protein induces platelet aggregation and supports platelet adhesion. Biochem Biophys Res Commun 1994;205:1829-1835.
195. Mattson MP, Guo ZH, Geiger JD. Secreted form of amyloid precursor protein enhances basal glucose and glutamate transport and protects against oxidative impairment of glucose and glutamate transport in synaptosomes by a cyclic GMP-mediated mechanism. J Neurochem 1999;73:532-537.
196. Puzzo D, Privitera L, Palmeri A. Hormetic effect of amyloid-beta peptide in synaptic plasticity and memory. Neurobiol Aging 2012;33:1484 e15–24.
197. Puzzo D, Arancio O. Amyloid-beta peptide: Dr. Jekyll or Mr. Hyde? J Alzheimers Dis 2013;33:(Suppl. 1): S111-S120.
198. Barco A, Pittenger C, Kandel ER. CREB, memory enhancement and the treatment of memory disorders: promises, pitfalls and prospects. Expert Opin Ther Targets 2003;7:101-114.
199. Cho EC, Mitton B, Sakamoto KM. CREB and leukemogenesis. Crit Rev Oncog 2011;16:37-46.